# A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

> **NCT07823608** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 258 (estimated)

## Conditions studied

- Apnea
- Sleep Disorders
- Overweight and/or Obesity

## Interventions

- **DRUG:** Berobenatide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07823608
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-06-18
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07823608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07823608, "A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07823608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
